Collectively, our results indicate that systemic PGRMC1 inhibition by 11α‐OHP improves metabolic outcomes even in advanced stages of diabetes, without apparent toxicity or non‐muscle‐specific adverse effects, underscoring its therapeutic potential. This evidence concerns the gene PGRMC1 and diabetes mellitus.